Back to All Events

Best of ASCO GI Cancer

  • The Darcy 1515 Rhode Island Avenue Northwest Washington, DC, 20005 United States (map)

Stay Tuned! Registration Opening Soon!

Hybrid Event | TBD CE/CME Credits & MOC Points

We invite you to join us for the Best of ASCO GI Cancer conference. This innovative and state of the art program is set completely in a multidisciplinary tumor board environment with some of the world's leading gastrointestinal cancer experts to discuss a variety of real-world cases —all while incorporating data from the major oncologic annual meetings. Expert panelists include surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, integrative medicine specialists, endocrinologists, geneticists, and patient advocates.

 
 

Conference Agenda
Saturday, April 5, 2025

8:00 AM
Coffee and Exhibits

8:30 AM
Program Chair Welcome

8:40 AM
Updates in Treatment for Colorectal Cancer

9:10 AM
What Are We Doing About Early Onset CRC?

9:40 AM
ctDNA Update: How Are We Utilizing This Technology?

10:00 AM
Breakfast and Exhibits

10:15 AM
Non-CME Breakfast

11:00 AM
Gastric and Esophageal Cancers: What is the Role of Immunotherapy?

11:30 AM
Is There a Role for Molecular Profiling in GI Cancers?

12:00 PM
An Evolving Role for HER2 in Gastric Cancer

12:20 PM
Lunch and Exhibits

12:35 PM
Non-CME Lunch

1:20 PM
Housekeeping and Survey

1:30 PM
Do We Still Need Adjuvant RT in GI Cancers?

2:00 PM
Pancreatic Cancer Treatment: Have We Made Any Progress?

2:30 PM
What's New in Hepatocellular Carcinoma?

3:00 PM
Novel Approaches in Hepatobiliary Cancers

3:30 PM
Networking Reception

4:40 PM
Adjourn

Agenda Subject To Change. All times are EST.

 
    • Review and analyze the latest therapeutic advances for the treatment and management of GI cancer.

    • Apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with GI cancers, neuroendocrine tumors, and hepatocellular cancers

    • Identify subpopulations of patients with gastrointestinal cancers most likely to benefit from a specific treatment plan based on prognostic or predictive markers

    • Evaluate the role of ctDNA and MRD in GI cancers

  • In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Nurses (ANCC) Credit Designation

    Amedco LLC designates this activity for a maximum of TBD ANCC contact hours.

    Physicians (ACCME) Credit Designation

    Amedco LLC designates this live activity for a maximum of TBD AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    Amedco LLC designates this activity for a maximum of TBD knowledge-based CPE contact hours.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

    American Board of Internal Medicine (ABIM) MOC Credit

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to TBD Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

    • Free registration for all healthcare providers

    • Expert sessions that present the most clinically relevant data, research, and clinical strategies

    • Real-time discussion and debate

    • Networking with peers, colleagues, and medical professionals

    • Access to the latest industry information and resources

 
Previous
Previous
April 5

Oncology Clinical Updates - Review and Renew

Next
Next
April 10

Cancer Updates GI and Breast